CMIC Co., Ltd. has announced a strategic partnership with Bluenote to deploy agentic artificial intelligence across clinical development workflows. The collaboration aims to support biopharma sponsors in improving the speed, quality, and scalability of clinical trial operations and regulatory submissions. The
Symeres has announced that it has received ISO/IEC 27001 certification, the international standard for information security management systems (ISMS), reinforcing its approach to protecting sensitive client data across its global operations. The certification comes as biopharmaceutical companies increasingly require stronger
FibroBiologics, Inc. has completed onboarding clinical sites for its Phase 1/2 clinical trial evaluating CYWC628, an investigational therapy for the treatment of refractory diabetic foot ulcers (DFUs). The prospective, multicenter, open-label study will assess the safety, tolerability, and efficacy of
Thermo Fisher Scientific has launched a Cryo-Electron Microscopy (cryo-EM) Drug Discovery Center in South San Francisco, California, aimed at helping pharmaceutical and biotechnology companies integrate structural biology into their drug discovery programs. The center is located in Oyster Point within the
Therna Biosciences has entered a collaboration with Charles River to advance personalized RNA medicines designed for individual patients with severe, ultra-rare disorders. The partnership focuses on developing therapeutic candidates tailored to a single patient’s genetic condition. The companies said the
PSI CRO, a Swiss-based global contract research organization (CRO), has opened a new office in Osaka, Japan, expanding its presence in the country. The facility is located on Level 18 of the Hilton Plaza West Office Tower in the Umeda
Sygnature Discovery, an integrated drug discovery contract research organisation (CRO), has announced the completion of a £1 million enhancement to its high-throughput chemistry (HTC) capabilities and laboratory infrastructure. The investment has resulted in a doubling of synthesis and purification capacity,
Evestia Clinical has announced a merger with US-based Atlantic Research Group (ARG), forming an enlarged global CRO group with expanded capabilities across therapeutic areas and clinical development phases. The merger, which more than doubles the size of the Group by
Momentum Biotechnologies has successfully acquired OmicScouts GmbH, a contract research organisation (CRO) based in Munich, Germany. The move strengthens Momentum’s position in mass spectrometry-based drug discovery and enables geographic expansion into the European market. OmicScouts will continue operations under its new name, OmicScouts,
AbbVie has announced a licensing agreement with Gubra to develop and commercialize GUB014295, a potential best-in-class, long-acting amylin analog for obesity treatment. The agreement marks AbbVie’s entry into the obesity market, an area of growing pharmaceutical focus. GUB014295, currently in a
